A CIRS commentary drawing on comparative research to examine the MHRA-NICE aligned pathway following its implementation in England.

Since 1 April 2026, the MHRA-NICE aligned pathway has been fully operational, marking an important step in the ongoing evolution of regulatory and health technology assessment (HTA) interaction in England.

For companies developing medicines and health technologies, the pathway introduces a new model of alignment that goes beyond coordination at submission alone. Instead, England is now explicitly pursuing alignment at the point of decision, with the MHRA and NICE aiming to publish licensing and value decisions at the same time.

CIRS has been examining regulatory-HTA interaction and alignment across jurisdictions for more than a decade. Against that background, the England experience offers an opportunity to observe how deeper alignment may influence development planning, assessment timelines, and decision making across a national system.

Parallel regulatory-HTA assessment: what is different this time?

Parallel regulatory and HTA processes are not new. Several jurisdictions already allow, or actively encourage, parallel submission, enabling regulators and HTA bodies to conduct assessments concurrently rather than sequentially.

However, one distinctive feature of the MHRA-NICE aligned pathway is the stated ambition for simultaneous decision making, rather than simply overlapping review timelines. This moves alignment further downstream in the lifecycle, creating the potential for more predictable outcomes for developers, healthcare systems, and patients.

CIRS’ recent comparative research provides some context for why this may matter. In an analysis of submissions in Australia and Canada, parallel regulatory and HTA submission was associated with faster rollout compared with traditional sequential approaches, as well as higher odds of an optimal HTA recommendation. While such findings are inherently context‑dependent, they suggest that alignment has the potential to influence both timing and outcomes under certain conditions.

The new pathway therefore presents an important real‑world case study, particularly given its ambition to align decision points rather than focusing solely on procedural coordination.

Alignment beyond submission: the role of integrated scientific advice

The aligned pathway also sits alongside an enhanced Integrated Scientific Advice service. Through a single entry point, companies can now obtain coordinated advice from MHRA and NICE at the same time.

Over recent years, CIRS research and multi‑stakeholder dialogue have highlighted the increasing value of early HTA input during development. Early engagement has been associated with clearer identification of potential evidence gaps, refinements to study design, and a better understanding of payer evidentiary expectations—particularly in areas of clinical or methodological uncertainty.

From a company perspective, coordinated regulatory-HTA advice has the potential to support more coherent development strategies, particularly where evidentiary requirements differ across jurisdictions or decision contexts.

How does this compare with the European landscape?

CIRS’ early advice study showed active company engagement with national HTA bodies such as NICE and G‑BA, alongside participation in previous European initiatives including the EUnetHTA Joint Actions.

Following the introduction of Joint Scientific Consultations (JSCs) under the EU HTA Regulation, companies and other stakeholders have generally viewed JSCs as an important mechanism for obtaining multi‑HTA input on the evidence generation during development and the PICO framework required for Joint Clinical Assessment (JCA) submissions. Companies also have the option to request EMA participation in JSC, to benefit from parallel regulatory and HTA advice. However, discussions have highlighted practical constraints to JSC, including limited availability and resource pressures from agencies, meaning not all intended requests from developers can be accommodated through this route.

In that context, the new MHRA-NICE integrated advice model may represent an additional opportunity for coordinated early dialogue. While it does not replace European processes, it may offer companies another route to gain timely insights, particularly for products with strong relevance to the England market.

What should stakeholders be watching?

As the MHRA-NICE aligned pathway is implemented in practice, several questions are likely to be of interest to regulators, HTA bodies, companies, and other stakeholders:

  • How consistently can aligned timelines and decisions be achieved across different types of products and therapeutic areas?
  • How is the new pathway aligning with existing regulatory and HTA initiatives, such as the MHRA International Recognition Procedure (IRP), and Innovative Licensing and Access Pathway (ILAP)?
  • To what extent does earlier and more integrated advice translate into changes in development design or evidence generation strategies?
  • What indicators will be used to measure success of the pathway? E.g. uptake of the pathway, timeline reductions etc.
  • What may be the influence on the HTA process in Scotland?
  • What impact, if any, will this model have on predictability of outcomes and overall time to patient access?

Answering these questions will require careful observation over time, as well as openness to refinement as operational experience grows.

Looking ahead

The launch of the MHRA-NICE aligned pathway represents a meaningful evolution in the regulatory-HTA environment in England. While alignment alone does not guarantee faster access or optimal outcomes, international experience suggests that how regulatory and HTA processes interact—and where alignment is pursued—can make a difference.

CIRS will continue to monitor developments in the UK and internationally, drawing on comparative research, such as our HTADock benchmarking study, and stakeholder dialogue to understand how different models of alignment influence development, decision making, and access.

Related CIRS Publications